Basilea berichtet positive Interim-Ergebnisse für Phase-2-Studie FIDES-01 mit Derazantinib bei Patienten mit Gallengangkrebs (iCCA) mit Mutationen oder Amplifikationen des FGFR2-Gens

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

Harshit Jain, MD
Programmatic Marketing